Published in

Taylor and Francis Group, Leukemia & Lymphoma, 6(58), p. 1358-1365

DOI: 10.1080/10428194.2016.1239259

Links

Tools

Export citation

Search in Google Scholar

The CDK inhibitor AT7519M in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. A Phase II study of the Canadian Cancer Trials Group

Journal article published in 2016 by Matthew D. Seftel, John Kuruvilla, Tom Kouroukis, Versha Banerji, Graeme Fraser, Michael Crump, Rajat Kumar, Haji I. Chalchal, Muhammad Salim, Rob C. Laister, Susan Crocker, Spencer B. Gibson, Marcia Toguchi, John F. Lyons, Hao Xu and other authors.
This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Red circle
Preprint: archiving forbidden
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO